Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Frequency, Characteristics and Prognostic Significance of RUNX1 mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified

Mi-Hyun Bae, MD PhD, Young-Uk Cho, MD PhD, Bohyun Kim, Dong Hyun Lee, Seongsoo Jang, MD PhD, Eul-Ju Seo, MD PhD, Chan-Jeoung Park, MD PhD, Dae-Young Kim, MD PhD, Jung-Hee Lee, MD PhD, Je-Hwan Lee, MD PhD, Kyoo-Hyung Lee, MD PhD, Yoon Hwan Chang, In-Suk Kim

Blood (2015) 126 (23): 3860.

https://doi.org/10.1182/blood.V126.23.3860.3860

Published: 2015

Journal Articles

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

Blood (2014) 124 (8): 1304–1311.

https://doi.org/10.1182/blood-2013-12-540716

Published: 2014

Includes: Supplemental data

Journal Articles

High-Risk AML, Including Flt3ITD+, Exhibits Resistance To Conventional Cytarabine Induction Associated With Diminished ENT1 and p16INK Expression: Evidence For Epigenetic Repression and HDAC Inhibitor Modulated De-Repression

H. Scott Boswell, MD, Sushil Gupta, Rui Gao, PhD, Katie J Sargent, Larry D. Cripe, MD, Mehdi Nassiri, MD, Hamid Sayar, MD, Yan Liu, PhD

Blood (2013) 122 (21): 2525.

https://doi.org/10.1182/blood.V122.21.2525.2525

Published: 2013

Journal Articles

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

Blood (2013) 122 (21): 608.

https://doi.org/10.1182/blood.V122.21.608.608

Published: 2013

Journal Articles

Detection of Copy Number Alterations in DNA Repair/Repair-Related Genes for a Diversity of Hematologic Malignancies Identifies Disease-Specific Biomarkers of Potential Clinical Relevance.

Roger A Schultz, PhD, Theresa C. Brown, PhD, Lynda J Campbell, Meaghan Wall, Jacqueline Schoumans, PhD, Jin-Yeong Han, MD, PhD, FASCP, Urvashi Surti, MD, S. Dwanna Stewart, PhD, FACMG, Min Fang, MD, PhD, James M Fink, MD, PhD, Raymond R. Tubbs, DO, James R. Cook, MD, PhD, Elena Gitelson, MD, PhD, Lisa D McDaniel, PhD, FACMG, Lisa G Shaffer, PhD, FACMG, Blake C Ballif, PhD

Blood (2012) 120 (21): 2531.

https://doi.org/10.1182/blood.V120.21.2531.2531

Published: 2012

Journal Articles

RUNX1 Mutations Reduce the Expression of CEBPA in Acute Myeloid Leukemia

Vera Grossmann, MSc, Alexander Kohlmann, PhD, Frank Dicker, PhD, Katrin Butschalowski, Wolfgang Kern, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2011) 118 (21): 2420.

https://doi.org/10.1182/blood.V118.21.2420.2420

Published: 2011

Journal Articles

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Panagiotis Kottaridis, MD, PhD, Maria Tsirogianni, MD, Janet North, BSc, MSc, Chloe Marden, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2011) 118 (21): 946.

https://doi.org/10.1182/blood.V118.21.946.946

Published: 2011

Journal Articles

Prevalence and Prognostic Impact of RUNX1 Mutations In Patients with Acute Myeloid Leukemia (AML): A Study In 1649 Patients Registered In the AML96 Protocol of the DSIL/SAL

Katharina Gerstenberger, Christoph Röllig, Markus Schaich, Thomas Illmer, Uwe Platzbecker, Martin Bornhäuser, Gerhard Ehninger, Christian Thiede

Blood (2010) 116 (21): 754.

https://doi.org/10.1182/blood.V116.21.754.754

Published: 2010

Journal Articles

IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia

Domenica Caramazza, Terra Lasho, MT, (ASCP), Christy Finke, Naseema Gangat, David Dingli, M.D., Ph.D., Ryan Knudson, Sergio Siragusa, MD, Curtis A. Hanson, MD, Animesh Pardanani, MBBS, PhD, Rhett Ketterling, Ayalew Tefferi, MD

Blood (2010) 116 (21): 4009.

https://doi.org/10.1182/blood.V116.21.4009.4009

Published: 2010

Journal Articles

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Jason C. Chandler, MD, Rebecca B. Klisovic, MD, Mitch A. Phelps, PhD, Alison Walker, MD, Ramiro Garzon, MD, Xiaoxia Yang, Larry Schaaf, PhD, Sebastian Schwind, MD, Heiko Becker, MD, Shujun Liu, PhD, Chris Hickey, Cheryl Kefauver, RN, Jon Mickle, CNP, Steven M Devine, MD, Michael R. Grever, MD, John C. Byrd, MD, Guido Marcucci, MD, William Blum, MD

Blood (2009) 114 (22): 841.

https://doi.org/10.1182/blood.V114.22.841.841

Published: 2009

Journal Articles

Epidemiological Study and Prognostic Markers in Patients Diagnosed with Chronic Ly Lmphocytic Leukemia. EPIGEN Study.

Mariola Abio, Gonzalo Caballero, Francisco Sala, Guillermina Hurtado, Jose A Marquez, Victoria Dourdil, Susana Arambarri, Filomena Floristan, Nicolas Gonzalez, Roberto Hernandez, Luis Lopez, Luis Perdiguer, Javier Marco, Francisco Sancho, Ignacio Olalla, Pilar Giraldo, MD

Blood (2009) 114 (22): 4398.

https://doi.org/10.1182/blood.V114.22.4398.4398

Published: 2009

Journal Articles

Non-Cycling Cells From Acute Myeloid Leukemia Patients Harbor the FLT3-ITD Mutation and Are Insensitive to TKI258, a Potent FLT3-Directed Inhibitor, in Vitro .

Caroline L Alvares, Tino Schenk, Sanna Hulkki, Toon Min, Gowri Vijayaraghavan, Yeung Jenny, David Gonzalez, Eric So, Mel Greaves, Ian Titley, Kerol Bartolovic, Gareth Morgan

Blood (2009) 114 (22): 479.

https://doi.org/10.1182/blood.V114.22.479.479

Published: 2009

Journal Articles

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

Todd A. Fehniger, John C. Byrd, Guido Marcucci, Camille N. Abboud, Cheryl Kefauver, Jacqueline E. Payton, Ravi Vij, William Blum

Blood (2009) 113 (5): 1002–1005.

https://doi.org/10.1182/blood-2008-04-152678

Published: 2009

Journal Articles

Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality

Ruben A. Mesa, Curtis A. Hanson, Rhett P. Ketterling, Susan Schwager, Ryan A. Knudson, Ayalew Tefferi

Blood (2009) 113 (5): 1200–1201.

https://doi.org/10.1182/blood-2008-10-182170

Published: 2009

Journal Articles

Recurrent Additional Genetic Aberrations and a Novel Mechanism of CBFB - MYH11 -Rearrangement in AML M4eo Are Detected Using High-Resolution Genome-Wide Single Nucleotide Polymorphisms (SNPs) Microarrays

Alexander Kohlmann, PhD, Sonja Rauhut, Frank Dicker, PhD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2008) 112 (11): 3115.

https://doi.org/10.1182/blood.V112.11.3115.3115

Published: 2008

Journal Articles

Somatic CNVs and LOH in Acute Myelomonocitic Leukemia

Alessandra Romano, Vincenza Barresi, Nicola Musso, Giuseppe A. Palumbo, Francesco Di Raimondo, Daniele Condorelli

Blood (2008) 112 (11): 4880.

https://doi.org/10.1182/blood.V112.11.4880.4880

Published: 2008

Journal Articles

Five New Pedigrees with Inherited RUNX1 Mutations Causing Familial Platelet Disorder with Propensity to Myeloid Malignancy (FPD/AML)

Carolyn J Owen, Cynthia L Toze, Anna Koochin, Donna L. Forrest, Clayton A. Smith, Shannon C Jackson, Man-Chiu Poon, Gary D. Sinclair, Brian Leber, Peter Johnson, Anthony Macheta, John AL Yin, Michael J. Barnett, T. Andrew Lister, Jude Fitzgibbon

Blood (2008) 112 (11): 5067.

https://doi.org/10.1182/blood.V112.11.5067.5067

Published: 2008

Journal Articles

Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.

Blood (2008) 112 (11): 1649.

https://doi.org/10.1182/blood.V112.11.1649.1649

Published: 2008

Journal Articles

RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG)

Verena I. Gaidzik, MD, Richard F. Schlenk, MD, Kerstin Wittke, Annegret Becker, Andreas Zimmermann, Brigitte Schlegelberger, MD, Arnold Ganser, MD, PhD, Daniela Spaeth, Hartmut Doehner, MD, Konstanze Doehner, MD

Blood (2008) 112 (11): 145.

https://doi.org/10.1182/blood.V112.11.145.145

Published: 2008

Journal Articles

Cooperating Molecular Mutations in AML1/RUNX1 Mutated AML Differ Dependent on the Cytogenetic Subgroup.

Susanne Schnittger, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2007) 110 (11): 365.

https://doi.org/10.1182/blood.V110.11.365.365

Published: 2007

NARROW

Frequency, Characteristics and Prognostic Significance of RUNX1 mutations in Patients with Acute Myeloid Leukemia, Not Otherwise Specified

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

High-Risk AML, Including Flt3ITD+, Exhibits Resistance To Conventional Cytarabine Induction Associated With Diminished ENT1 and p16INK Expression: Evidence For Epigenetic Repression and HDAC Inhibitor Modulated De-Repression

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

Detection of Copy Number Alterations in DNA Repair/Repair-Related Genes for a Diversity of Hematologic Malignancies Identifies Disease-Specific Biomarkers of Potential Clinical Relevance.

RUNX1 Mutations Reduce the Expression of CEBPA in Acute Myeloid Leukemia

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Prevalence and Prognostic Impact of RUNX1 Mutations In Patients with Acute Myeloid Leukemia (AML): A Study In 1649 Patients Registered In the AML96 Protocol of the DSIL/SAL

IDH Mutations and Trisomy 8 In Myelodysplastic Syndromes and Acute Myeloid Leukemia

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Epidemiological Study and Prognostic Markers in Patients Diagnosed with Chronic Ly Lmphocytic Leukemia. EPIGEN Study.

Non-Cycling Cells From Acute Myeloid Leukemia Patients Harbor the FLT3-ITD Mutation and Are Insensitive to TKI258, a Potent FLT3-Directed Inhibitor, in Vitro .

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality

Recurrent Additional Genetic Aberrations and a Novel Mechanism of CBFB - MYH11 -Rearrangement in AML M4eo Are Detected Using High-Resolution Genome-Wide Single Nucleotide Polymorphisms (SNPs) Microarrays

Somatic CNVs and LOH in Acute Myelomonocitic Leukemia

Five New Pedigrees with Inherited RUNX1 Mutations Causing Familial Platelet Disorder with Propensity to Myeloid Malignancy (FPD/AML)

Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.

RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG)

Cooperating Molecular Mutations in AML1/RUNX1 Mutated AML Differ Dependent on the Cytogenetic Subgroup.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only